Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- PHIO
- Price
- 1.08
- Stock movement up
- +0.04 (3.85%)
- Company name
- Phio Pharmaceuticals Corp
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 11.92M
- Ent value
- 2.88M
- Price/Sales
- 170.33
- Price/Book
- 1.21
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -65.05%
- 1 year return (CAGR)
- -56.45%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-01-22
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
PHIO does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 170.33 |
| Price to Book | 1.21 |
| EV to Sales | 41.20 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 11.04M |
| EPS (TTM) | -0.15 |
| FCF per share (TTM) | -0.13 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 70.00K |
| Gross profit (TTM) | -1.04M |
| Operating income (TTM) | -8.36M |
| Net income (TTM) | -7.95M |
| EPS (TTM) | -0.15 |
| EPS (1y forward) | -1.26 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -1487.14% |
| Operating margin (TTM) | -11942.86% |
| Profit margin (TTM) | -11361.43% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 10.71M |
| Net receivables | 0.00 |
| Total current assets | 11.49M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 11.51M |
| Accounts payable | 516.00K |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 516.00K |
| Total liabilities | 1.67M |
| Shareholder's equity | 9.84M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -7.27M |
| Capital expenditures (TTM) | 13.00K |
| Free cash flow (TTM) | -7.28M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -80.83% |
| Return on Assets | -69.13% |
| Return on Invested Capital | -80.83% |
| Cash Return on Invested Capital | -74.03% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.06 |
| Daily high | 1.10 |
| Daily low | 1.05 |
| Daily Volume | 306K |
| All-time high | 490050.00 |
| 1y analyst estimate | 14.00 |
| Beta | 0.89 |
| EPS (TTM) | -0.15 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| PHIO | S&P500 | |
| Current price drop from All-time high | -100.00% | -0.89% |
| Highest price drop | -100.00% | -19.00% |
| Date of highest drop | 22 Jan 2026 | 8 Apr 2025 |
| Avg drop from high | -100.00% | -2.49% |
| Avg time to new high | - | 6 days |
| Max time to new high | 322 days | 89 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
11.92M
Marketcap category
Small-cap
Description
Phio Pharmaceuticals Corp., a a clinical stage biotechnology company, engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts.
Employees
5
Website
Investor relations
SEC filings
CEO
Gerrit Dispersyn
Country
USA
City
Marlborough
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page